LOGICAL EVIDENCE THAT MASS VACCINATION ALSO OF THE LOW-RISK GROUP IN COVID-19 IS SUBOPTIMAL CONTAINS TWO KEY IMMUNOLOGICAL/VIROLOGICAL/EPIDEMIOLOGICAL STARTING POINTS, BOTH OF WHICH CONCERN THE BROAD T-CELL IMMUNITY TO CONSERVED INTERNAL VIRAL PROTEINS IN DIFFERENT VIRAL VARIANTS OF SARS-COV-2
LOGICAL EVIDENCE THAT MASS VACCINATION ALSO OF THE LOW-RISK GROUP IN COVID-19 IS SUBOPTIMAL CONTAINS TWO KEY IMMUNOLOGICAL/VIROLOGICAL/EPIDEMIOLOGICAL STARTING POINTS, BOTH OF WHICH CONCERN THE BROAD T-CELL IMMUNITY TO CONSERVED INTERNAL VIRAL PROTEINS IN DIFFERENT VIRAL VARIANTS OF SARS-COV-2
LOGICAL EVIDENCE THAT MASS VACCINATION ALSO OF THE LOW-RISK GROUP IN COVID-19 IS SUBOPTIMAL CONTAINS TWO KEY IMMUNOLOGICAL/VIROLOGICAL/EPIDEMIOLOGICAL STARTING POINTS, BOTH OF WHICH CONCERN THE BROAD T-CELL IMMUNITY TO CONSERVED INTERNAL VIRAL PROTEINS IN DIFFERENT VIRAL VARIANTS OF SARS-COV-2
https://www.facebook.com/permalink.php?story_fbid=pfbid026DukZo5BXDsR2SeKkb1NkJcSDV74vzwC7GgaMMBaEsX85xr2KYjtcyACpzKzBbLl&id=100014130274974